Abstract

Alnylam Pharmaceuticals will report fiscal second-quarter 2026 results on July 30, 2026 Pre-Market; investors will focus on revenue momentum, profitability, and progress across core RNAi franchises and partnerships.

Market Forecast

Consensus modeled from the company’s guidance and market tracking points to current-quarter revenue of 1.32 billion US dollars with an estimated year-over-year increase of 101.50%, EBIT of 0.29 billion US dollars with an estimated year-over-year increase of 506.41%, and adjusted EPS of 1.56 with an estimated year-over-year increase of 315.79%. Gross margin is expected to remain structurally high, while net profit or margin is projected to improve moderately from last quarter’s level; year-over-year comparisons are slated to be favorable. Main business highlights emphasize continued expansion of product revenues within the RNAi portfolio and stable contributions from collaboration and licensing revenue streams. The most promising segment is product revenue, projected to lead growth on the back of increased patient starts and geographic expansion, while collaboration and licensing provide incremental upside.

Last Quarter Review

In the prior quarter, Alnylam Pharmaceuticals reported revenue of 1.17 billion US dollars, a gross profit margin of 81.91%, GAAP net profit attributable to the parent company of 0.21 billion US dollars, a net profit margin of 17.65%, and adjusted EPS of 1.51, all showing strong year-over-year trajectories. A key highlight was outperformance versus internal and external expectations, with revenue exceeding consensus and solid operational leverage driving an EBIT beat. Main business performance was led by product revenue of 1.04 billion US dollars, supplemented by contract revenue of 82.08 million US dollars and licensing revenue of 48.97 million US dollars, reflecting robust demand across the RNAi franchise.

Current Quarter Outlook (with major analytical insights)

Main business: Product revenue from RNAi therapeutics

Product revenue remains the primary driver, underpinned by continued adoption of the company’s approved RNAi therapies and ongoing market expansions. The last quarter’s 1.04 billion US dollars in product sales and high-80s proportion of total revenue set a strong base, and the current quarter’s forecast implies sustained momentum with a potential mix shift toward chronic therapies with higher adherence. Management’s ability to execute on patient identification, payer access, and real-world persistence will be critical to maintaining revenue quality and predictability. Price dynamics appear stable, suggesting volume growth will be the larger determinant of upside.

Most promising segment: Scaling patient starts and geographic expansion

The acceleration in patient starts, supported by increased physician awareness and broader reimbursement coverage, positions this segment for the fastest incremental growth. Geographic expansion initiatives, particularly in markets with newly secured pricing and access, can unlock additional demand without significant near-term margin trade-offs, given the platform’s established manufacturing base. With forecast revenue growth above 100.00% year over year, execution in launch geographies and expanded indications will likely be the key swing factors for top-line outperformance.

Stock-price drivers this quarter: Profitability and margin durability

Investors are set to scrutinize the sustainability of margins, given last quarter’s 81.91% gross margin and 17.65% net margin. With EBIT estimated at 0.29 billion US dollars and adjusted EPS expected at 1.56, incremental operating leverage from scale and disciplined opex could be a catalyst if revenue lands at or above guidance. Conversely, any signal of higher commercial expenses to support launches, or lumpiness in collaboration revenue, could pressure quarterly margins and sentiment despite a high structural gross margin.

Analyst Opinions

The balance of recent institutional commentary skews bullish, with the majority highlighting durable revenue growth from the RNAi portfolio, improving operating leverage, and a favorable catalysts calendar that could support estimate revisions. Analysts emphasize the combination of strong product momentum and partnership upside as key reasons to expect beats on revenue and profitability, while acknowledging normal quarterly variability in collaboration payments. The bullish camp argues that high-visibility revenue, coupled with expanding patient populations and continued geographic penetration, provides a supportive setup for upside to consensus in the upcoming print and into the back half of the year.